This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.
Footnotes
Mol Cancer Ther 2019;18:1909–15
- Received March 7, 2019.
- Revision received June 11, 2019.
- Accepted September 4, 2019.
- Published first November 1, 2019.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 18, Issue 11
Jump to section
- Article
- Abstract
- Rationale for Inhibiting EGFR in SCCHN
- The Limitations of Anti-EGFR Targeting in SCCHN
- Resistance Mechanisms to EGFR Inhibition
- Emergence of Immunotherapy as an Effective Therapeutic Modality in SCCHN
- Immune Implications of EGFR Targeting
- Forging the Alliance
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics